Lipidomics Shared Resource

Lipidomics共享资源：摘要 Lipidomics共享资源（LSR）的使命是提供具有成本效益的先进方法， 最先进的仪器，以及在生物活性脂质的合成和分析方面的专业知识， cer中心（HCC）成员。LSR的科学目标是为研究脂质代谢提供资源 和信号传导，用于鉴定生物活性脂质及其在肿瘤细胞生物学中的作用，并用于发现 以及评估针对脂质代谢过程的药物。通过提供深入的探索以及高 通过脂质组学的选择来分析癌细胞和组织，结合教育研讨会， LSR促进HCC基础，临床和人口科学家之间的互动。保持领先地位 作为一个不断发展的领域，自上次审查以来，LSR通过投资新设备（Thermo TSQ-50003，SCIEX Q-Trap三重四极/离子阱，Advion TriVersa Nanomat）和转移设备 从Cell & Molecular Imaging Shared Resource到LSR，将MALDI成像服务添加到LSR（布鲁克 Faltonics AutoFlex III线性MALDI和AutoFLexIII MALDI TOF-TOF）。在当前周期中，LSR- 直接支持了45篇与癌症相关的出版物，三个团队科学项目，多个内部资助的团队， 基于项目，三个个人癌症赠款，两个转化研究和一个1期临床试验。下 在Besim Ogretmen博士的领导下，LSR已经发展成为一个国内和国际公认的 拥有先进的测量和分析生物活性脂质分子的新方法， 与癌症的发生和发展有关。Ogretmen是脂质生物学领域的国家领导者， 主要关注鞘脂，包括鞘糖脂。LSR集成了MALDI成像功能， 组织中鞘脂种类的直接组织分析，肿瘤异种移植组织和器官中的药物分布 （脑、肾、肝），并通过碰撞诱导片段对目标药物或代谢物进行结构确认， 是的。因此，通过结合质谱和MALDI成像，该资源不仅可以量化鞘氨醇， 组织中的磷脂，但也可以提供关于它们在组织中的细胞位置和分布的信息。的 LSR准备好推进和支持肝癌癌症研究中重要的新兴科学学科 成员和更广泛的科学界。

LIPIDOMICS SHARED RESOURCE: SUMMARY The mission of the Lipidomics Shared Resource (LSR) is to provide cost-effective advanced methodology, state-of-the-art instrumentation, and expertise in the synthesis and analysis of bioactive lipids to Hollings Can- cer Center (HCC) members. The scientific goal of the LSR is to provide resources for studying lipid metabolism and signaling in cancer, for identifying bioactive lipids and their role in tumor cell biology, and for discovering and evaluating drugs that target lipid metabolic processes. By providing deep exploratory as well as high throughput lipidomic options to analyze cancer cells and tissues, combined with educational workshops, the LSR fosters interactions among basic, clinical and population scientists at HCC. To remain at the leading edge of an evolving field, since the last review, the LSR expanded services by investing in new equipment (Thermo TSQ-50003, SCIEX Q-Trap triple quadrupole/ion trap, Advion TriVersa Nanomat) and transferring equipment from the Cell & Molecular Imaging Shared Resource to LSR, adding MALDI imaging services to LSR (Bruker Faltonics AutoFlex III linear MALDI, and AutoFLexIII MALDI TOF-TOF). During the current cycle, the LSR di- rectly supported 45 cancer-related publications, three team science projects, multiple internally funded team- based projects, three individual cancer grants, two translational studies, and one phase 1 clinical trial. Under the leadership of Besim Ogretmen, PhD, the LSR has grown to become a nationally- and internationally-recog- nized scientific resource with novel sophisticated methods for measurement and analysis of bioactive lipid mol- ecules relevant to cancer initiation and progression. Ogretmen is a national leader in lipid biology with a partic- ular focus on sphingolipids, including glycosphingolipids. The LSR has integrated MALDI imaging capability for direct tissue analysis of sphingolipid species in tissues, drug distribution in tumor xenograft tissue and organs (brain, kidney, liver), and structure confirmation of drug or metabolite of interest by collision-induced fragmenta- tion. Thus, by combining mass spectrometry and MALDI imaging, this resource not only quantifies sphin- golipids in tissues, but can also provide information about their cellular location and distribution in tissues. The LSR is well poised to advance and support important emerging scientific disciplines in cancer research to HCC members and the broader scientific community.